Compared Efficacy of Prazepam and Clomipramine in Major Depression with Anxiety: a Multicenter Controlled Study

Lemoine, P.; Boulenger, J.-P.; Caillard, Vincent; Tanne, Nicole; Bonnet, D

doi:10.1055/s-2007-1014464

Cited by 8 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Firstly, the study lacked a positive antidepressant control. Nevertheless, the observed quantified outcomes on various psychometric measures of efficacy in this study are consistent with the activity of an antidepressant, not a nonspecific agent (Lemoine et al, 1991). In addition, the time course of response, although observed early in the course of treatment, was gradually progressive as typically seen with antidepressants.…”

Section: Discussionsupporting

confidence: 77%

Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression

Kramer

Winokur

Kelsey

et al. 2003

Neuropsychopharmacol

246

140

View full text Add to dashboard Cite

The efficacy and safety of a selective NK 1 antagonist, L-759274, was investigated in outpatients with diagnosis of major depressive disorder with melancholic features, following evidence obtained with the novel compound aprepitant that Substance P (NK 1 ) antagonists may provide a unique mechanism of antidepressant activity. A randomized, double-blind placebo-controlled study was carried out. Patients, male or female, aged 18-60, scoring X25 points on total of first 17 items of 21-item Hamilton Depression Scale (HAMD), and scoring X4 (moderately ill) on Clinical Global Impressions-Severity Scale were randomized to oral L-759274 40 mg daily (n ¼ 66) or placebo (n ¼ 62) for 6 weeks. For patients receiving L-759274, improvement (mean decrease from baseline) in HAMD-17 total score was 10.7 points, compared with a mean 7.8 point improvement in patients receiving placebo (po0.009). Mean scores for item 1 of HAMD-17 (depressed mood) also improved to a greater extent in the active group compared with the placebo group (0.3 points, po0.058). Compared with placebo, mean scores on Clinical Global Impressions-Improvement Scale improved significantly by the end of the trial (p ¼ 0.009). L-759274 was generally safe and well-tolerated. The incidence of sexual side effects was on par with that observed in patients receiving placebo, and the incidences of gastrointestinal effects were low. Antidepressant actions have now been observed with two different highly selective NK 1 antagonists (aprepitant and L-759274). NK 1 antagonism is a replicated and generally welltolerated antidepressant mechanism.

show abstract

Section: Discussionsupporting

confidence: 77%

Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression

Kramer

Winokur

Kelsey

et al. 2003

Neuropsychopharmacol

246

140

View full text Add to dashboard Cite

show abstract

“…From the benzodiazepines, in general, contradictory clinical results with respect to their antidepressant activity are published but nevertheless with a slightly positive outcome. [56][57][58][59][60], There are sever al publications in which an antipsychotic effect is de scribed for (higher doses of) benzodiazepines, alone [61] or, more especially, in combination with neuroleptics [62][63][64][65][66]. This automatic classification system did not rec ognize antipsychotic characteristics, but the power in crease from 10/15 to 25/30 Hz may be an indication for this activity.…”

Section: Discussionmentioning

confidence: 99%

Classification of Psychotropic Drugs Based on Pharmaco-electrocorticographic Studies in Vigilance-Controlled Rats

1993

View full text Add to dashboard Cite

The effects of a number of psycho-active drugs on electrocorticographic activity (ECoG) of the rat have been studied. Frontoparietal ECoG was recorded during 6-min periods immediately before drug/vehicle administration and starting at 20 and 45 min after administration. For each 6-min recording time, a mean power spectrum was calculated and smoothed. A quotient of the power at 20 and 45 min after and before drug, respectively, was then calculated. These quotients were used as input for an analysis of variance, followed by a t test and a normalization for the degrees of freedom, resulting in so-called n-profiles. Although each drug has its own characteristic n-profile, n-profiles of drugs belonging to the same clinical class have some characteristics in common. An automated classification system of psychotropic drugs, based on parameters extracted from n-profiles by discriminant analysis, is presented. For the antidepressant drug class the success rate of correct classification of antidepressant drugs is between 53 and 88%, for a neuroleptic drug in the neuroleptic drug class the success rate is 87%, for an anxiolytic drug in the anxiolytic drug class 100% and for a psychostimulant drug in the psycho-stimulant drug class between 86 and 100%. For a reliable classification of a drug about 10 n-profiles of active doses are needed. Using n-profiles, it appeared also possible to discriminate between antidepressant, neuroleptic, anxiolytic and psychostimulant drugs based on visual judgement. Moreover, visual evaluation of the n-profiles enables 4 subclasses to be recognized within the antidepressant class, 2 subclasses within the neuroleptic and 2 subclasses within the anxiolytic class.

show abstract

“…Seven reports directly compared BZD and TCA in patients suffering from mixed anxiety/ depressive states [34][35][36][37], neurotic depression [38,39], and DSM-III major depressive disorder with anxiety [40] (online suppl. Table 1).…”

Section: Systematic Review Of Rct On the Efficacy Of Bzd In The Treatmentioning

confidence: 99%

“…In 5 studies [35,[37][38][39][40], there were no significant differences between BZD and TCA. Results significantly favoring TCA over BZD were found in the remaining 2 studies [34,36].…”

Section: Systematic Review Of Rct On the Efficacy Of Bzd In The Treatmentioning

confidence: 99%

Benzodiazepines as a Monotherapy in Depressive Disorders: A Systematic Review

Benasi¹,

Guidi²,

Offidani³

et al. 2018

Psychother Psychosom

View full text Add to dashboard Cite

Background: The aim of this paper was to perform a systematic review and, when feasible, a meta-analysis of randomized controlled trials (RCT) which used benzodiazepines (BZD) as a monotherapy versus placebo, antidepressant drugs (AD), or both. Methods: Keyword searches were conducted for identifying RCT comparing BZD and AD, and/or placebo in the treatment of depression, using electronic databases from their inception up to April 2017. We selected reports of RCT in which BZD were compared to AD and/or placebo in the treatment of adult patients with a primary diagnosis of depressive disorder or anxious depression. When feasible, data were subjected to meta-analysis. Results: A total of 38 studies met the criteria for inclusion and were then included in the systematic review. Only 1 study concerned a newer AD, fluvoxamine. For the meta-analysis, we submitted data on response rate from 22 RCT, considering BZD versus placebo (8 comparisons) and BZD versus tricyclic antidepressants (TCA) (20 comparisons). There was a lack of significant differences as to response rate between BZD and placebo, as well as between BZD and TCA. Analysis of individual studies disclosed that, in more than half of the studies comparing BZD to TCA and/or placebo, BZD were significantly more effective than placebo and as effective as TCA. Conclusions: BZD are a therapeutic option in anxious depression and there are no indications that AD are preferable. There is a pressing need for RCT of adequate methodological quality and follow-up comparing BZD to second-generation AD and placebo in anxious depression.

show abstract

Compared Efficacy of Prazepam and Clomipramine in Major Depression with Anxiety: a Multicenter Controlled Study

Cited by 8 publications

References 15 publications

Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression

Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression

Classification of Psychotropic Drugs Based on Pharmaco-electrocorticographic Studies in Vigilance-Controlled Rats

Benzodiazepines as a Monotherapy in Depressive Disorders: A Systematic Review

Contact Info

Product

Resources

About